Not Yet Recruiting
ALDOA Expression in Bladder Urothelial Carcinoma
NCT06550947
- Conditions
- Bladder Urothelial Carcinoma
- Locations
-
Not specified
Clinical trial condition
Bladder Urothelial Carcinoma
Explore clinical trials studying Bladder Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.
26 public trials
7 recruiting studies
Bladder Urothelial Carcinoma trial results
Not Yet Recruiting
Bladder Preservation With Sacituzumab Govitecan + Zimberelimab for Muscle-Invasive Bladder Cancer
NCT06528483
- Conditions
- Bladder Cancer, Bladder Neoplasm, Bladder Urothelial Carcinoma, +12 more
- Locations
-
- Fondazione Irccs Istituto Nazionale Dei Tumori Di Milano Milan, Italy
NCT02989064
- Conditions
- Bladder Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +20 more
- Locations
-
- Massachusetts General Hospital Boston, Massachusetts, United States
- Washington University - School of Medicine St Louis, Missouri, United States
- Roswell Park Cancer Institute Buffalo, New York, United States
- Ohio State University Wexner Medical Center Columbus, Ohio, United States
Completed
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
NCT03039413
- Conditions
- Bladder Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +4 more
- Locations
-
- Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia, Pennsylvania, United States
NCT04570410
- Conditions
- Bladder Urothelial Carcinoma
- Locations
-
- The first affiliated hospital of Nanjing Medical University Nanjing, Jiangsu, China
NCT05788484
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bladder Urothelial Carcinoma, +64 more
- Locations
-
- George Washington University Cancer Center Washington D.C., District of Columbia, United States
- AdventHealth Celebration Celebration, Florida, United States
- Perlmutter Cancer Center at NYU Langone Health New York, United States
- Providence Cancer Institute Portland, Oregon, United States
Completed
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
NCT03473730
- Conditions
- Adenocarcinoma, Bladder Urothelial Carcinoma, Carcinoma, +18 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Completed
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
NCT03329950
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bile Duct Diseases, +120 more
- Locations
-
- HonorHealth Research Insititute Scottsdale, Arizona, United States
- Northside Hospital, Inc. Atlanta, Georgia, United States
- Georgia Cancer Center at Augusta University Augusta, Georgia, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha, Nebraska, United States
NCT04200963
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Bladder Cancer, +35 more
- Locations
-
- Banner Health- MD Anderson Cancer Center Gilbert, Arizona, United States
- Florida Cancer Specialists - Sarasota Sarasota, Florida, United States
- Rush University Medical Center Chicago, Illinois, United States
- Johns Hopkins Kimmel Cancer Center Baltimore, Maryland, United States
Completed
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
NCT04440943
- Conditions
- Adenocarcinoma, Adnexal Diseases, Bladder Urothelial Carcinoma, +61 more
- Locations
-
- Northside Hospital Atlanta, Georgia, United States
- University of Chicago Chicago, Illinois, United States
- Oncology Hematology West, PC dba Nebraska Cancer Specialists Omaha, Nebraska, United States
- Duke Cancer Center Durham, North Carolina, United States